Newsroom
Articles > Stock News: GeneDx (WGS) Investors Face Securities Class Action Lawsuit Deadline
- Faruqi & Faruqi, LLP reminds GeneDx (WGS) investors of the August 3, 2026, deadline for a securities class action lawsuit.
- Hagens Berman investigates claims against GeneDx Holdings (WGS) following a 49% stock collapse.
- Robbins Geller Rudman & Dowd LLP announces an opportunity for investors with substantial losses to lead the class action lawsuit against GeneDx.
- Pomerantz Law Firm reminds investors with losses in GeneDx Holdings Corp. of the upcoming deadlines for the class action lawsuit.
- GeneDx Holdings faces lawsuits from various law firms due to alleged securities fraud and misrepresentations.
Investors who suffered losses in GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, are urged to take action before the August 3, 2026, deadline in a securities class action lawsuit. Faruqi & Faruqi, LLP, a national securities law firm, is actively investigating potential claims against GeneDx and reminds investors of the looming deadline to seek the role of lead plaintiff in the federal securities class action.
Following a massive impairment charge and a 49% stock collapse on May 5, 2026, Hagens Berman (HBSS), a prominent securities litigation leader, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives. The lawsuit alleges that the defendants misled investors about the Fabric Genomics acquisition and synergy potential, leading to substantial losses.
Robbins Geller Rudman & Dowd LLP has announced that investors with significant losses have an opportunity to lead the class action lawsuit against GeneDx Holdings. Purchasers of GeneDx common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as a lead plaintiff in the GeneDx class action lawsuit.
Pomerantz Law Firm, another legal entity, has filed a class action lawsuit against GeneDx Holdings Corp., advising investors with losses on their investment to take action before the upcoming deadlines. Investors who purchased or acquired GeneDx securities between April 16, 2025, and May 4, 2026, are encouraged to contact the firm to discuss their legal rights and potential compensation.
Various law firms, including Kahn Swick & Foti, LLC and Rosen Law Firm, are also urging GeneDx Holdings Corp. investors to take action before the important deadline in a securities class action lawsuit. Investors with substantial losses are reminded to file lead plaintiff applications if they purchased or acquired the company's shares between April 16, 2025, and May 4, 2026, the period in question for the class action lawsuit.
In the midst of increasing legal scrutiny and investor allegations of securities fraud and misrepresentations, GeneDx Holdings Corp. continues to face mounting pressure from multiple law firms. Investors are advised to stay informed and consider their legal options before the deadline to seek potential compensation.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Stock News: GeneDx (WGS) Investors Face Securities Class Action Lawsuit Deadline
By KlickAnalytics Data Insights | June 30, 2026 08:03PM ET
Key Points
- Faruqi & Faruqi, LLP reminds GeneDx (WGS) investors of the August 3, 2026, deadline for a securities class action lawsuit.
- Hagens Berman investigates claims against GeneDx Holdings (WGS) following a 49% stock collapse.
- Robbins Geller Rudman & Dowd LLP announces an opportunity for investors with substantial losses to lead the class action lawsuit against GeneDx.
- Pomerantz Law Firm reminds investors with losses in GeneDx Holdings Corp. of the upcoming deadlines for the class action lawsuit.
- GeneDx Holdings faces lawsuits from various law firms due to alleged securities fraud and misrepresentations.
Investors who suffered losses in GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, are urged to take action before the August 3, 2026, deadline in a securities class action lawsuit. Faruqi & Faruqi, LLP, a national securities law firm, is actively investigating potential claims against GeneDx and reminds investors of the looming deadline to seek the role of lead plaintiff in the federal securities class action.
Following a massive impairment charge and a 49% stock collapse on May 5, 2026, Hagens Berman (HBSS), a prominent securities litigation leader, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives. The lawsuit alleges that the defendants misled investors about the Fabric Genomics acquisition and synergy potential, leading to substantial losses.
Robbins Geller Rudman & Dowd LLP has announced that investors with significant losses have an opportunity to lead the class action lawsuit against GeneDx Holdings. Purchasers of GeneDx common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as a lead plaintiff in the GeneDx class action lawsuit.
Pomerantz Law Firm, another legal entity, has filed a class action lawsuit against GeneDx Holdings Corp., advising investors with losses on their investment to take action before the upcoming deadlines. Investors who purchased or acquired GeneDx securities between April 16, 2025, and May 4, 2026, are encouraged to contact the firm to discuss their legal rights and potential compensation.
Various law firms, including Kahn Swick & Foti, LLC and Rosen Law Firm, are also urging GeneDx Holdings Corp. investors to take action before the important deadline in a securities class action lawsuit. Investors with substantial losses are reminded to file lead plaintiff applications if they purchased or acquired the company's shares between April 16, 2025, and May 4, 2026, the period in question for the class action lawsuit.
In the midst of increasing legal scrutiny and investor allegations of securities fraud and misrepresentations, GeneDx Holdings Corp. continues to face mounting pressure from multiple law firms. Investors are advised to stay informed and consider their legal options before the deadline to seek potential compensation.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.